These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 12531322)

  • 21. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
    Brenzel L
    Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Australia's contribution to global immunisation.
    Ruff TA; Taylor K; Nolan T
    Aust N Z J Public Health; 2012 Dec; 36(6):564-9. PubMed ID: 23216498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GAVI gears up for record replenishment.
    Usher AD
    Lancet; 2014 Jul; 384(9939):219-20. PubMed ID: 25050437
    [No Abstract]   [Full Text] [Related]  

  • 24. Vaccine Assistance To Low- And Middle-Income Countries Increased To $3.6 Billion In 2014.
    Haakenstad A; Birger M; Singh L; Liu P; Lim S; Ng M; Dieleman JL
    Health Aff (Millwood); 2016 Feb; 35(2):242-9. PubMed ID: 26858376
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global support for new vaccine implementation in middle-income countries.
    Kaddar M; Schmitt S; Makinen M; Milstien J
    Vaccine; 2013 Apr; 31 Suppl 2():B81-96. PubMed ID: 23598496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tracking donor funding towards achieving the Global Vaccine Action Plan (GVAP) goals: A landscape analysis (1990-2016).
    Ikilezi G; Zlavog B; Augusto OJ; Sherr K; Lim SS; Dieleman JL
    Vaccine; 2018 Nov; 36(49):7487-7495. PubMed ID: 30366804
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches.
    Watts E; Sim SY; Constenla D; Sriudomporn S; Brenzel L; Patenaude B
    Value Health; 2021 Jan; 24(1):78-85. PubMed ID: 33431157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of the Global Alliance for Vaccines and Immunisation on diphtheria, tetanus, and pertussis vaccine coverage: an independent assessment.
    Lu C; Michaud CM; Gakidou E; Khan K; Murray CJ
    Lancet; 2006 Sep; 368(9541):1088-95. PubMed ID: 16997663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why The Decade Of Vaccines?
    Health Aff (Millwood); 2016 Feb; 35(2):188-9. PubMed ID: 26858368
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey.
    Dorleans F; Giambi C; Dematte L; Cotter S; Stefanoff P; Mereckiene J; O'Flanagan D; Lopalco PL; D'Ancona F; Levy-Bruhl D;
    Euro Surveill; 2010 Nov; 15(47):. PubMed ID: 21144444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strengthening legal frameworks for vaccination: The experiences of Armenia, Georgia, and Moldova.
    Trumbo SP; Silver D; Domenti O; Gasoyan H; Paatashvili E; Gellin BG; Gordon JL
    Vaccine; 2019 Aug; 37(35):4840-4847. PubMed ID: 30392764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New immunization initiatives and progress toward the global control of hepatitis B.
    Kane MA; Brooks A
    Curr Opin Infect Dis; 2002 Oct; 15(5):465-9. PubMed ID: 12686877
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Strengthening vaccination policies in Latin America: an evidence-based approach.
    Tapia-Conyer R; Betancourt-Cravioto M; Saucedo-Martínez R; Motta-Murguía L; Gallardo-Rincón H
    Vaccine; 2013 Aug; 31(37):3826-33. PubMed ID: 23357196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of cost-effectiveness analysis for pediatric immunization in developing countries.
    Gauvreau CL; Ungar WJ; Köhler JC; Zlotkin S
    Milbank Q; 2012 Dec; 90(4):762-90. PubMed ID: 23216430
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The announcement by the GAVI Alliance Board to support human papillomavirus (HPV) vaccines in the world's poorest countries.
    Vaccine; 2012 Nov; 30 Suppl 4():xii. PubMed ID: 23510773
    [No Abstract]   [Full Text] [Related]  

  • 36. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
    Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
    Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shifts in global immunisation goals (1984-2004): unfinished agendas and mixed results.
    Hardon A; Blume S
    Soc Sci Med; 2005 Jan; 60(2):345-56. PubMed ID: 15522490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estimating the costs of implementing the rotavirus vaccine in the national immunisation programme: the case of Malawi.
    Madsen LB; Ustrup M; Hansen KS; Nyasulu PS; Bygbjerg IC; Konradsen F
    Trop Med Int Health; 2014 Feb; 19(2):177-85. PubMed ID: 24314006
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advocating for efforts to protect African children, families, and communities from the threat of infectious diseases: report of the First International African Vaccinology Conference.
    Wiysonge CS; Waggie Z; Hawkridge A; Schoub B; Madhi SA; Rees H; Hussey G
    Pan Afr Med J; 2016; 23():53. PubMed ID: 27217879
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction.
    Shen AK; Weiss JM; Andrus JK; Pecenka C; Atherly D; Taylor K; McQuestion M
    Health Aff (Millwood); 2016 Feb; 35(2):272-6. PubMed ID: 26858380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.